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Introduction {#cam4767-sec-0001}
============

As of 2012, breast cancer (70,170), prostate cancer (63,710), colorectal cancer (62,230) and lung cancer (52,520) rank highest in terms of incidence case numbers of malignancies in Germany [1](#cam4767-bib-0001){ref-type="ref"}. Accordingly, these entities have been in the focus of funding agencies, the pharmaceutical industries, and preventive programs. Germany has witnessed a major demographic shift over the last decades. Changes in the population structure influence the projections of cancer cases in the future. For the United States, Smith and coworkers projected a significant increase in cancer incidences for the years 2020 and 2030. This projection was based on the fact that there are sociodemographic changes ongoing in the United States, such as a dramatic increase in the number of elderly citizens and minorities [2](#cam4767-bib-0002){ref-type="ref"}. Recently, Rahib and colleagues took a similar approach and expanded the projections made by Smith et al. Rahib et al. included not only demographic changes, but also changes in age‐standardized incidence rates by cancer type [3](#cam4767-bib-0003){ref-type="ref"}. Based on these variables, different projections of future cancer incidence and deaths were made. Rahib et al. projected an unexpected and alarming rise of thyroid, liver, and pancreatic cancer, the latter becoming the second most frequent cause of cancer‐related deaths around 2021. International publications of similar projections for Germany are rare [4](#cam4767-bib-0004){ref-type="ref"}, [5](#cam4767-bib-0005){ref-type="ref"}, [6](#cam4767-bib-0006){ref-type="ref"}, [7](#cam4767-bib-0007){ref-type="ref"}, [8](#cam4767-bib-0008){ref-type="ref"}; therefore, such projections could add substantial weight to future global health initiatives. Accordingly, we set out to adapt and improve the projection model established by Rahib and colleagues to calculate the future cancer burden in Germany.

Materials and Methods {#cam4767-sec-0002}
=====================

Data preparation {#cam4767-sec-0003}
----------------

For this study, cancer registry data from the Robert Koch Institute [9](#cam4767-bib-0009){ref-type="ref"} and demographic projections from the Federal Statistical Office of Germany (published 28 April 2015) were used [10](#cam4767-bib-0010){ref-type="ref"}. Within the Robert Koch Institute, the German Centre for Cancer Registry Data are responsible for pooling and quality assurance of the data from population‐based cancer registries in each of the German federal states. These data were retrieved by database query (<http://www.krebsdaten.de>).

Age‐standardized incidence rates and age‐specific incidence rates, as well as the case numbers for the 15 most common cancer sites (ICD 10 classification) were provided for the years 1999--2011. Age‐standardized mortality rates and age‐specific mortality rates, as well as the death numbers for the 15 most common malignancies were provided for the years 1998--2012. Rates were standardized using the old European Standard Population. Age‐specific rates for each site were grouped by sex and 5‐year age group (from 0 to 84 or 85+ years). Both age‐standardized and age‐specific rates were computed per 100,000 individuals. The standard errors of the age‐standardized rates, which are required for the trend analysis (joinpoint regression) described below, were calculated from the corresponding age‐specific rates and age‐specific population sizes by means of a SAS program (SAS version 9.4, Cary, NC).

Population projections for 2020 and 2030 were provided by the Federal Statistical Office of Germany, which is responsible for collection, processing, and analysis of statistical information concerning economy, society, and environment. Eight different population projections were provided. Here, the G1‐L1‐W1 projection was used, assuming a birth rate of 1.4 children per woman, life expectancy at birth in 2060 of 84.8 years for men and 88.8 years for women, as well as a long‐term net migration of 100,000 individuals per year.

Trend analysis {#cam4767-sec-0004}
--------------

To analyze changes in cancer incidence and mortality, age‐standardized cancer incidence rates from 1999 to 2011 and age‐standardized cancer mortality rates from 1998 to 2012 were modeled into joinpoint regression, which is applied to detect points of changing trends (joinpoints) and determine the linear trends between these points. For the calculations, we used a freely available software tool from the National Cancer Institute [11](#cam4767-bib-0011){ref-type="ref"}, [12](#cam4767-bib-0012){ref-type="ref"}. The joinpoint software selected the best‐fitting trend pattern, that is, the number of time points within the range of years at which the linear trend changes, for each cancer site. The average annual percent change (AAPC) was calculated by summarizing the trend over the time period as weighted average of the annual percent changes (APCs). The AAPC calculations were done for the entire age range, that is, not specific for age groups. This approach was taken because the numbers of cancer‐site‐specific incident cases (or deaths) are rather small (less than 100 or even less than 10 cases) for many age‐specific groups of a 5‐year age range. Therefore, performing the estimation for such rather small age‐specific groups would lead to a considerable variance and instability in the age‐group‐specific AAPC(j) estimates, which is likely to outweigh the apparent advantage of an age‐specific AAPC modeling.

Projected cancer incidence {#cam4767-sec-0005}
--------------------------

Cancer incidences were projected based on the methods applied by Rahib and colleagues [3](#cam4767-bib-0003){ref-type="ref"}. Based on the assumption that the pattern of changes in cancer incidence and death rate remain consistent into the future, these projections combine past AAPCs with present age‐specific numbers of incident cases or deaths and projected demographic developments. In contrast to Rahib et al., AAPCs in incidence rates that were not significantly different from zero were still used in the projections in order to avoid any bias. The following formulas were used to project incidences for 2020 and 2030. $$\text{For}\mspace{6mu}\text{AAPC}_{i} > 0:\,\#\,\text{of\ Cases} = I_{d}\left( {\frac{\text{AAPC}_{i}}{100} + 1} \right)^{n}$$ $$\text{For}\mspace{6mu}\text{AAPC}_{i} < 0:\,\#\,\text{of\ Cases} = \frac{I_{d}}{{({\frac{{|AAP}C_{i}|}{100} + 1})}^{n}}$$

*AAPC* ~*i*~ was calculated by the joinpoint software [12](#cam4767-bib-0012){ref-type="ref"} for each cancer site by sex. The variable *n* equals the adjustment in years, which is 9 for 2020 and 19 for 2030, respectively. *I* ~*d*~ is the incidence based on the projected demographics [10](#cam4767-bib-0010){ref-type="ref"} for 2020 and 2030, which equals the sum of the age‐specific incidence rate of year 2011 for each age group *j* multiplied by the corresponding age‐specific population of 2020 and 2030. $$I_{d} = \sum_{j = x}^{y}\text{Incidence}\mspace{6mu}\text{rate}_{2011,j}\, \cdot \text{Population}_{2020\, or\, 2030,j}$$

Projected cancer‐related deaths {#cam4767-sec-0006}
-------------------------------

To project cancer‐related deaths, the same algorithm as for incidence projections was applied, with the difference that the mortality data were collected for the period from 1998 to 2012. This approach differs from the methods applied by Rahib and colleagues [3](#cam4767-bib-0003){ref-type="ref"}. More specifically, age‐specific mortality rates of year 2012 were used to calculate *D* ~*d*~. The adjustment *n* was changed accordingly to 8 and 18 years for 2020 and 2030, respectively. The following formulas were used to project the number of cancer‐related deaths by 2020 and 2030. $$\text{For}\mspace{6mu}\text{AAPC}_{d} > 0:\,\#\,\text{of\ Deaths} = D_{d} \cdot \left( {\frac{\text{AAPC}_{d}}{100} + 1} \right)^{n}$$ $$\text{For}\mspace{6mu}\text{AAPC}_{d} < 0:\,\#\,\text{of\ Deaths} = \frac{D_{d}}{{({\frac{{|AAP}C_{d}|}{100} + 1})}^{n}}$$ $$D_{d} = \sum_{j = x}^{y}\text{Mortality\ rate}\mspace{6mu}_{2012,j}\, \cdot \text{Population}_{2020\, or\, 2030,j}$$

Results and Discussion {#cam4767-sec-0007}
======================

Cancer incidence {#cam4767-sec-0008}
----------------

Table [1](#cam4767-tbl-0001){ref-type="table-wrap"} and Figure [1](#cam4767-fig-0001){ref-type="fig"} depict the projected incidences in 2020 and 2030, based on changing demographics and the change in AAPCs for the 14 most common cancer sites in women, men, and combined for both sexes. In both sexes combined (Fig. [1](#cam4767-fig-0001){ref-type="fig"} A and B), the incidence of most cancers is projected to increase until 2030. Based on our projections, prostate cancer will surpass breast cancer, becoming the most frequent malignancy by 2030. Furthermore, lung cancer will surpass colorectal cancer, thus ranking third most common cancer by 2030. Thyroid cancer will increase notably, exceeding liver and ovary cancer to become the 10th most frequent entity in 2030.

###### 

Incidence projections based on demographic changes and AAPCs in incidence rates

  Cancer sites                         Men        Women     All                  
  ------------------------------------ ---------- --------- ---------- --------- ---------
  All cancer sites (C00‐C97 w/o C44)                                             
  2011                                 0          255,318   0.5        228,259   483,577
  2020                                 283,976    254,360   538,336              
  2030                                 312,597    280,876   593,473              
  Breast (C50)                                                                   
  2011                                 0.5        594       1          69,663    70,257
  2020                                 703        80,077    80,780               
  2030                                 818        91,200    92,018               
  Cervix uteri (C53)                                                             
  2011                                                      **−1.8**   4647      4647
  2020                                            4023      4023                 
  2030                                            3924      3924                 
  Colon and rectum (C18‐C21)                                                     
  2011                                 −0.8       34,276    **−1.1**   28,695    62,971
  2020                                 36,104     28,419    64,523               
  2030                                 39,938     30,696    70,634               
  Kidney (C64)                                                                   
  2011                                 −0.5       9034      0          5593      14,627
  2020                                 9441       6003      15,444               
  2030                                 10,168     6390      16,558               
  Leukemia (C91‐C95)                                                             
  2011                                 0.2        7533      0.2        5965      13,498
  2020                                 8477       6266      14,743               
  2030                                 9525       6494      16,019               
  Liver (C22)                                                                    
  2011                                 1.1        5764      **1.6**    2994      8758
  2020                                 7119       3758      10,877               
  2030                                 8781       4803      13,584               
  Lung (C33‐C34)                                                                 
  2011                                 −1.5       35,141    **3.3**    17,576    52,717
  2020                                 34,374     25,451    59,825               
  2030                                 37,745     37,056    74,801               
  Malignant melanoma of skin (C43)                                               
  2011                                 3.2        10,247    2.8        10,101    20,348
  2020                                 14,541     13,179    27,720               
  2030                                 21,358     17,569    38,927               
  Ovary (C56)                                                                    
  2011                                                      **−1.7**   7819      7819
  2020                                            7116      7116                 
  2030                                            7447      7447                 
  Pancreas (C25)                                                                 
  2011                                 0.3        8240      **1.3**    7970      16,210
  2020                                 9552       9789      19,341               
  2030                                 10,831     12,156    22,987               
  Prostate (C61)                                                                 
  2011                                 **2.1**    64,515                         64,515
  2020                                 86,551               86,551               
  2030                                 121,335              121,335              
  Stomach (C16)                                                                  
  2011                                 **−2.6**   9573      **−2.7**   6453      16,026
  2020                                 8603       5535      14,138               
  2030                                 9485       5974      15,459               
  Testis (C62)                                                                   
  2011                                 **1.9**    4139                           4139
  2020                                 4695                 4695                 
  2030                                 5216                 5216                 
  Thyroid gland (C73)                                                            
  2011                                 **4.6**    1791      **4.4**    4467      6258
  2020                                 2735       6534      9269                 
  2030                                 4318       9822      14,140               

AAPC, average annual percent change. The bold AAPCs indicated a significant difference from 0 at *α*= 0.05 level.
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In women (Fig. [1](#cam4767-fig-0001){ref-type="fig"}C), breast cancer is projected to remain the most common malignancy with constant increase in case numbers over the next two decades. Furthermore, lung cancer will surpass colorectal cancer to rank second most frequent malignancy in 2030.

Among men (Fig. [1](#cam4767-fig-0001){ref-type="fig"}D), prostate cancer will remain the most common cancer and will continuously increase in incidence over the next two decades. While cases of colorectal and lung cancer will remain fairly stable, pancreatic cancer will surpass kidney and stomach cancer to become the fifth most common cancer by 2030 (Table [1](#cam4767-tbl-0001){ref-type="table-wrap"}).

Cancer‐related deaths {#cam4767-sec-0009}
---------------------

Projections for cancer‐related deaths caused by the 14 most frequent malignancies in women and men for the years 2020 and 2030 can be found in Table [2](#cam4767-tbl-0002){ref-type="table-wrap"} and Figure [2](#cam4767-fig-0002){ref-type="fig"}. Overall (Fig. [2](#cam4767-fig-0002){ref-type="fig"}A and B), lung cancer will remain the major cause of cancer‐related mortality and the number of deaths will steadily increase until 2030. By 2030, pancreatic cancer will surpass colorectal and breast cancer to rank second most common cause of cancer‐related deaths. Our calculations project a sharp increase in deaths due to liver cancer (sixth), surpassing stomach cancer, which will constantly decrease and fall behind leukemia (seventh) to rank eighth most common cause of cancer‐related deaths by 2030.

###### 

Death projections based on demographic changes and AAPCs in death rates

                                       Men        Women     All                  
  ------------------------------------ ---------- --------- ---------- --------- ---------
  All cancer sites (C00‐C97 w/o C44)                                             
  2012                                 **−1.8**   119,717   **−1.2**   101,206   220,923
  2020                                 117,780    99,835    217,615              
  2030                                 110,119    96,119    206,238              
  Breast (C50)                                                                   
  2012                                 **−5.4**   150       **−1.5**   17,748    17,898
  2020                                 111        16,903    17,014               
  2030                                 72         15,689    15,761               
  Cervix uteri (C53)                                                             
  2012                                                      **−2.3**   1617      1617
  2020                                            1416      1416                 
  2030                                            1153      1153                 
  Colon and rectum (C18‐C21)                                                     
  2012                                 **−2.7**   13,772    **−3.4**   12,200    25,972
  2020                                 12,743     10,319    23,062               
  2030                                 11,035     8137      19,172               
  Kidney (C64)                                                                   
  2012                                 **−2.3**   3125      **−2.3**   2131      5256
  2020                                 2963       1937      4901                 
  2030                                 2624       1699      4323                 
  Leukemia (C91‐C95)                                                             
  2012                                 **−1.4**   4155      **−1.6**   3445      7600
  2020                                 4263       3317      7581                 
  2030                                 4149       3092      7241                 
  Liver (C22)                                                                    
  2012                                 **1**      5117      **0.9**    2553      7670
  2020                                 6140       2992      9133                 
  2030                                 7581       3551      11,132               
  Lung (C33‐C34)                                                                 
  2012                                 **−2**     29,713    **2.6**    14,752    44,465
  2020                                 28,202     19,542    47,745               
  2030                                 25,620     26,870    52,490               
  Malignant melanoma of skin (C43)                                               
  2012                                 **1.1**    1627      0.3        1248      2875
  2020                                 1956       1366      3321                 
  2030                                 2421       1503      3925                 
  Ovary (C56)                                                                    
  2012                                                      **−1.5**   5646      5646
  2020                                                      5356       5356      
  2030                                                      4959       4959      
  Pancreas (C25)                                                                 
  2012                                 **0.2**    7936      **0.9**    8184      16,120
  2020                                 8992       9612      18,603               
  2030                                 10,209     11,517    21,726               
  Prostate (C61)                                                                 
  2012                                 **−2.3**   12,957                         12,957
  2020                                 13,059               13,059               
  2030                                 12,120               12,120               
  Stomach (C16)                                                                  
  2012                                 **−4.1**   5770      **−4.4**   4208      9978
  2020                                 4764       3257      8020                 
  2030                                 3545       2313      5859                 
  Testis (C62)                                                                   
  2012                                 −1.1       179                            179
  2020                                 173                  173                  
  2030                                 154                  154                  
  Thyroid gland (C73)                                                            
  2012                                 −2.6       330       **−4.4**   419       749
  2020                                 303        326       629                  
  2030                                 259        232       491                  

AAPC, average annual percent change. The bold AAPCs indicated a significant difference from 0 at *α*= 0.05 level.
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In women (Fig. [2](#cam4767-fig-0002){ref-type="fig"}C), lung cancer will surpass breast cancer (second) to become the most frequent cause of female cancer deaths. Pancreatic cancer will exceed colorectal cancer (fourth) to rank third most common cause of cancer‐related deaths in female patients.

In men (Fig. [2](#cam4767-fig-0002){ref-type="fig"}D), numbers of cancer‐related deaths are fairly stable with the exception of pancreatic cancer, liver cancer, and melanoma (Table [2](#cam4767-tbl-0002){ref-type="table-wrap"}). Lung cancer will remain the most frequent cause of cancer‐related deaths in men, albeit with a projected decrease toward 2030. Deaths due to pancreatic cancer are constantly rising, approaching the numbers of colorectal cancer (third).

In this study, we used a combination of demographic projections, present numbers of incident cases or deaths, and weighted annual percent changes to project cancer incidence and deaths in Germany in the future. Such projections are based on several assumptions and thus prone to systematical errors. First, demographic projections are based on current developments and past trends. Hence, in addition to the projection G1‐L1‐W1, as a sensitivity analysis we have also modeled cancer incidences and death rates based on the G2‐L2‐W2 assumption (birth rate 1.6 children per woman, life expectancy at birth in 2060 of 86.7 years for men and 90.4 years for women, long‐term net migration 200,000 individuals per year), which leads to the same conclusions that were obtained using G1‐L1‐W1 (data not shown). Accordingly, we assume that moderate variations in demographic assumptions, such as the recent changes in immigration, are not strong enough to substantially alter the projected disease patterns.

Second, we, as others, assumed that AAPCs in incidence and death rates will remain constant until 2030. While this seems far‐fetched at first sight, we based our AAPC calculations on an expanded time period of 12 years for incidence and 14 years for mortality. Therefore, we are confident that future trends are in line with the development in the past, at least approximately. Nevertheless, while upcoming interventions such as improved cancer prevention and novel screening modalities can have a major influence on future incidence and mortality, they cannot be modeled realistically with current knowledge.

Projected trends in different entities {#cam4767-sec-0010}
--------------------------------------

There are several interpretations and explanations for the projections presented here. Prostate cancer is a disease of the elderly, and thus one of the underlying reasons for the increase in incidence is the aging German population. However, there are two forms---indolent and aggressive prostate cancer. Population screening behaviors can appreciably affect incidence rates in discovering more indolent than aggressive disease, but have relatively less effect on mortality, which is largely due to aggressive disease. Thus, in spite of a high prevalence, mortality due to prostate cancer will remain fairly stable [13](#cam4767-bib-0013){ref-type="ref"}. Breast cancer has been on the rise over the past decades. Based on our projections this trend will continue. Accordingly, breast cancer will remain the most common cancer in women and the second most common cancer averaged over both sexes. Nevertheless, early detection as well as improved management has led to an improvement in the prognosis of patients suffering from breast cancer [1](#cam4767-bib-0001){ref-type="ref"}. Tobacco smoking is the major risk factor for lung cancer. Smoking among women has steadily increased since the 1960s. Accordingly, the projected increase in female lung cancer cases and deaths is the reflection of this trend [14](#cam4767-bib-0014){ref-type="ref"}. The projected stabilization in incidence and decrease in deaths due to colorectal cancer are reflecting both improved screening modalities and treatment options even for patients with advanced disease [15](#cam4767-bib-0015){ref-type="ref"}. Primary cancers of the liver, including hepatocellular carcinoma and intrahepatic cholangiocarcinoma, are a global health burden. Accordingly, the projected increase in these entities is alarming because they are usually detected at an advanced state and curative treatment options are limited [16](#cam4767-bib-0016){ref-type="ref"}, [17](#cam4767-bib-0017){ref-type="ref"}. Germany has seen a 50% increase in liver cancers over the past 30 years, which might be attributed not only to known risk factors, such as liver cirrhosis due to chronic hepatitis or alcohol consumption, but also to the emergence of nonalcoholic steatohepatitis (NASH) caused by overweight and obesity [18](#cam4767-bib-0018){ref-type="ref"}. Finally, in accordance with projections by Rahib and colleagues [3](#cam4767-bib-0003){ref-type="ref"}, we expect the same dramatic increase in pancreatic cancer‐related deaths in Germany by 2030. Pancreatic ductal adenocarcinoma (PDAC) remains an almost uniformly lethal disease with a 5‐year survival rate in the single digits. Although two landmark trials within the last 5 years yielded positive results for patients with metastatic PDAC, the overall prognosis remains dismal [19](#cam4767-bib-0019){ref-type="ref"}. Aging of the population, as well as modifiable risk factors such as smoking and obesity, only partly account for the growing number in pancreatic cancer cases and the consecutive deaths due to the disease [20](#cam4767-bib-0020){ref-type="ref"}. It has been suggested that PDAC has a long latency between initiation and metastatic potential [21](#cam4767-bib-0021){ref-type="ref"}. Thus, early detection of pancreatic cancer might help to offer potentially curative surgery for a larger number of patients. In this light, a recent publication on exosomes as an early and specific marker identifying patients with pancreatic cancer is of great interest [22](#cam4767-bib-0022){ref-type="ref"}. Nevertheless, novel diagnostic and therapeutic modalities as well as scientific efforts are desperately needed to meet the upcoming challenge projected here.

Recently, Rahib and colleagues reported incidence and death rates based on AAPCs for the United States [3](#cam4767-bib-0003){ref-type="ref"}. While we modified and applied their methodical approach, used consistent methods to project deaths similar to incidence case numbers, and also decided to include nonsignificant AAPCs in our projections. In contrast, Rahib and coworkers set these AAPCs to zero. Accordingly, their projections for cancers with nonsignificant AAPCs are just based on demographic changes. Furthermore, and in contrast to the above‐mentioned authors, we have used longer time periods (12 years for incidence and 14 years for mortality) to calculate the AAPCs.

Nevertheless, we project the same alarming increase in pancreatic cancer‐related deaths for Germany as Rahib et al. previously found for the United States. Furthermore, we project a similar growing number of deaths for liver cancer, although this trend does not reach the magnitude of the projection for the U.S. This is most probably due to some differences between the United States and Germany, weaker rises (1% per year for men and 0.9% per year for women) in terms of AAPCs and a comparatively low baseline value (7670 deaths in 2012). Similarly, our projections show a marked increase in the incident case number of thyroid cancers. However, possibly due to the comparatively low baseline value and differences in the population structure, this increase in thyroid cancer incidence is not as pronounced as in the United States.

In the past, a couple of projections based on demographic changes estimating the future cancer burden in Germany have been published [4](#cam4767-bib-0004){ref-type="ref"}, [5](#cam4767-bib-0005){ref-type="ref"}, [6](#cam4767-bib-0006){ref-type="ref"}, [7](#cam4767-bib-0007){ref-type="ref"}, [8](#cam4767-bib-0008){ref-type="ref"}. However, most of these projections were not based on past trend changes in cancer incidence and mortality [5](#cam4767-bib-0005){ref-type="ref"}, [7](#cam4767-bib-0007){ref-type="ref"}, [8](#cam4767-bib-0008){ref-type="ref"}. Haberland et al. [4](#cam4767-bib-0004){ref-type="ref"} combined past trend changes in cancer mortality with projections on estimated changes in future demographics for the five most common cancers. The investigators predicted lower numbers of cancer‐related deaths for 2020, most probably because different methods and older data versions were used. Although the study by Haberland et al. used log‐linear models to capture the past trend in cancer incidence and mortality, we decided to perform joinpoint regression, which allows for periods having different trends during the past. These stepwise trends are assumed to be linear on a logarithmic scale rather than modeled as quadratic polynomials as in the approach taken by Haberland et al. [4](#cam4767-bib-0004){ref-type="ref"}. We believe that a stepwise linear fit of past trends, followed by averaging the annual percent change over the different periods, is likely to lead to a more realistic extrapolation of incidence and mortality rates into the future than employing a single log‐linear fit over the entire period in one single step that includes quadratic terms, because overfitting is more likely to occur. In concordance with our findings, Haberland et al. also showed the increase in lung cancer deaths in women and decrease in stomach and colon cancer deaths in women and men. Nowossadeck et al. [6](#cam4767-bib-0006){ref-type="ref"} combined past trend changes in cancer incidence and changes in future demographics for two cancer locations up to 2020 using only slightly older datasets than the data underlying this study. Their projected numbers for colon and lung cancer are similar to our results. Going beyond these two cancer locations, we present the first study in Germany with a more comprehensive approach taking 14 different cancer types into consideration.

In summary, we have applied mathematical modeling to project a scenario for the future cancer burden in Germany. While there is a fundamental difference in terms of demographic structure, we see comparable trends to the United States, especially with regard to a considerable rise in pancreatic cancer incidence and mortality. These projections might be helpful to direct scientific and medical efforts to meet the challenges of cancer prevention and treatment in the future.
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